Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854320 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL671091 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854304 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL17931825 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL9961490 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL16968414 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL16491025 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL27398 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL13998184 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854383 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| CN-117903386-A | Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition | 厦门碳控科技投资有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4294447-A1 | POLYSACCHARIDE COMPLEX | Acaryon GmbH (DE) | 2023-12-27 | — | — | EP | claimed |
| CN-117157100-A | Polysaccharide complexes | 阿卡扬股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2022175390-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2022-08-25 | — | — | WO | claimed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | claimed |
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | claimed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | claimed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | claimed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | claimed |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | claimed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010107519-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088268-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | PDE4A 4326/4885LMNA 4457/4885L3MBTL1 1047/4885 |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | PDE4A 2432/4885LMNA 1448/4885L3MBTL1 3218/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | PDE4A 3569/4885LMNA 1669/4885L3MBTL1 295/4885 |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | PNKP, ADAR, NCL | PDE4A 1267/4885LMNA 934/4885L3MBTL1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.